A Double Hit CD10-Negative B-Cell Lymphoma with t3;8q27;q24 Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical OutcomeReportar como inadecuado




A Double Hit CD10-Negative B-Cell Lymphoma with t3;8q27;q24 Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Case Reports in Hematology - Volume 2014 2014, Article ID 120714, 5 pages -

Case Report

Department of Haematology, University Hospitals of Leicester, Leicester LE1 5WW, UK

Ernest and Helen Scott Haematological Research Institute and Department of Biochemistry, University of Leicester, Leicester LE1 9HN, UK

Christian-Albrechts-University Kiel and Universitatsklinikum Schleswig-Holstein, Campus Kiel, Arnold Heller Straße 3, 24105 Kiel, Germany

Ernest and Helen Scott Haematological Research Institute and Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE1 9HN, UK

Received 8 August 2014; Accepted 15 September 2014; Published 1 October 2014

Academic Editor: Takashi Sonoki

Copyright © 2014 Lucinda Sanders et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The WHO classification of lymphomas allows for a group of diseases that have features intermediate between those of Burkitt lymphoma and diffuse large B-cell lymphoma. These are a diverse group of diseases whose genetics and clinical course are yet to be fully described. We report an unusual case of high grade B-cell lymphoma, intermediate between DLBCL and BL, lacking CD10 expression in which the chromosomal translocation t3;8q27;q24 was found to be the sole chromosomal abnormality. FISH analysis demonstrated juxtaposition of the BCL6 and MYC loci without obvious involvement of the IGH locus, suggesting constitutive MYC expression due to promoter substitution. The patient responded to intensive chemotherapy and remains in remission two years after finishing therapy.





Autor: Lucinda Sanders, Sandrine Jayne, Ben Kennedy, Fiona Miall, Sietse M. Aukema, Reiner Siebert, Simon D. Wagner, and Martin J.

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados